Want to see GB:GENF full AI Analyst Report?

Genflow Biosciences Plc (GENF) Price & Analysis

12 Followers

GENF Stock Chart & Stats

1.68 p

0.00 p(0.00%)

At close: Jul 31 4:00 PM EDT

1.68 p

0.00 p(0.00%)

Day’s Range― - ―

52-Week Range0.62 p - 3.12 p

Previous CloseN/A

Volume3.08M

Average Volume (3M)1.73M

Market Cap

£11.19M

Enterprise Value11.62M

Total Cash (Recent Filing)£111.79K

Total Debt (Recent Filing)£0.00

Price to Earnings (P/E)―

Beta-0.13

Next Earnings

Sep 25, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding566,409,800

10 Day Avg. Volume2,042,393

30 Day Avg. Volume1,733,703

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)-14.33

Price to Sales (P/S)0.00

P/FCF Ratio-5.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

IP ProtectionExpanding patent coverage around SIRT6 variants, delivery technologies, and indications can strengthen barriers to entry and support future partnering potential as Genflow advances its longevity platform.

Preclinical ValidationPositive durability and safety signals in an aging model improve the credibility of Genflow’s therapeutic approach and may support progression toward additional studies, partnerships, and broader pipeline validation.

Non-Dilutive PartnershipAccess to funded delivery expertise can accelerate development while reducing immediate dilution and internal infrastructure needs, strengthening execution capacity for a platform that depends on effective gene delivery.

Bears Say

Pre-Revenue ModelThe absence of commercial revenue leaves Genflow dependent on research milestones and external financing rather than recurring operating income, making its financial outlook highly sensitive to development success and timing.

Persistent Cash BurnSustained cash consumption limits self-funding capacity and implies continued reliance on capital raising, partnerships, or other external sources to maintain development programs over the medium term.

Negative EquityAccumulated losses have overwhelmed the capital base, reducing balance-sheet resilience and financial flexibility. Although debt is zero, negative equity increases dependence on new funding to sustain operations and pipeline investment.

Genflow Biosciences Plc News

Genflow Advances SIRT6 Patent Portfolio to Bolster Longevity Gene Therapy Strategy

The latest announcement is out from Genflow Biosciences Plc ( ($GB:GENF) ). Genflow Biosciences, a UK-based biotechnology firm...

24d ago

Genflow advances SIRT6 longevity platform with positive dog data and new partnerships

Genflow Biosciences Plc ( ($GB:GENF) ) has provided an update. Genflow Biosciences reported that its SIRT6-centric longevity platform...

1M ago

Genflow Wins Strong Shareholder Backing for Governance and New Share Scheme

Genflow Biosciences Plc ( ($GB:GENF) ) has provided an update. Genflow Biosciences reported that shareholders approved all resolutions...

2M ago

Genflow’s Chair to Spotlight Longevity and RNA Therapeutics at BIO 2026

Genflow Biosciences Plc ( ($GB:GENF) ) has provided an update. Genflow Biosciences said its independent non-executive chairman, Gad...

2M ago

Genflow to Unveil Key Beagle Longevity Trial Data at Animal Summit 2026

Genflow Biosciences Plc ( ($GB:GENF) ) has issued an announcement. Genflow Biosciences will present data from its SLAB...

2M ago

Genflow Sets June AGM and Announces Board Change Amid Longevity R&D Push

Genflow Biosciences Plc ( ($GB:GENF) ) has provided an announcement. Genflow Biosciences Plc, a UK-based longevity-focused biotech with...

3M ago

Genflow Biosciences expands share capital after warrant exercises

An update from Genflow Biosciences Plc ( ($GB:GENF) ) is now available. Genflow Biosciences announced the exercise of...

4M ago

Genflow Advances SIRT6 Longevity Pipeline as Funding and Canine Trial Progress Bolster Position

Genflow Biosciences Plc ( ($GB:GENF) ) just unveiled an update. Genflow Biosciences reported significant operational progress in 2025,...

4M ago

Genflow widens Tier-1 animal health review of canine gene therapy

Genflow Biosciences Plc ( ($GB:GENF) ) just unveiled an announcement. Genflow Biosciences has expanded its network of confidentiality...

4M ago

Genflow Secures Fully Funded LNP Collaboration With Acuitas to Advance SIRT6 Gene Therapy

Genflow Biosciences Plc ( ($GB:GENF) ) just unveiled an announcement. Genflow Biosciences has entered a strategic technology collaboration...

4M ago

GENF FAQ

What was Genflow Biosciences Plc’s price range in the past 12 months?

Genflow Biosciences Plc lowest share price was 0.62 p and its highest was 3.12 p in the past 12 months.

What is Genflow Biosciences Plc’s market cap?

Genflow Biosciences Plc’s market cap is £11.19M.

When is Genflow Biosciences Plc’s upcoming earnings report date?

Genflow Biosciences Plc’s upcoming earnings report date is Sep 25, 2026 which is in 30 days.

How were Genflow Biosciences Plc’s earnings last quarter?

Genflow Biosciences Plc released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.

Is Genflow Biosciences Plc overvalued?

According to Wall Street analysts Genflow Biosciences Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Genflow Biosciences Plc pay dividends?

Genflow Biosciences Plc does not currently pay dividends.

What is Genflow Biosciences Plc’s EPS estimate?

Genflow Biosciences Plc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Genflow Biosciences Plc have?

Genflow Biosciences Plc has 566,409,800 shares outstanding.

What happened to Genflow Biosciences Plc’s price movement after its last earnings report?

Genflow Biosciences Plc reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.071%.

Which hedge fund is a major shareholder of Genflow Biosciences Plc?

Currently, no hedge funds are holding shares in GB:GENF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genflow Biosciences Plc

Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.